NCT00907166 2017-03-21A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer PatientsCornerstone PharmaceuticalsPhase 1/2 Terminated6 enrolled
NCT01832857 2016-12-29Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer PatientsCornerstone PharmaceuticalsPhase 2 Terminated7 enrolled